Aneta Cymbaluk-PÅ,oska

List of Publications by Year
in descending order

46 papers	466 citations
758635	839053
12 h-index	18 g-index
46 all docs	46 docs citations
46 times ranked	618 citing authors

#	Article	IF	Citations
1	The Role of Zinc and Copper in Gynecological Malignancies. Nutrients, 2020, 12, 3732.	1.7	57
2	Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer. Journal of Ovarian Research, 2018, 11, 1.	1.3	48
3	Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer. OncoTargets and Therapy, 2018, Volume 11, 1363-1372.	1.0	27
4	Circulating Serum Level of Visfatin in Patients with Endometrial Cancer. BioMed Research International, 2018, 2018, 1-9.	0.9	24
5	Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer. Disease Markers, 2017, 2017, 1-8.	0.6	21
6	Fertility Preservation and Long-Term Monitoring of Gonadotoxicity in Girls, Adolescents and Young Adults Undergoing Cancer Treatment. Cancers, 2021, 13, 202.	1.7	18
7	The sFlt-1/PlGF ratio values within the <38, 38–85 and >85 brackets as compared to perinatal outcomes. Journal of Perinatal Medicine, 2019, 47, 732-740.	0.6	17
8	Molecular Pathways of Cellular Senescence and Placental Aging in Late Fetal Growth Restriction and Stillbirth. International Journal of Molecular Sciences, 2021, 22, 4186.	1.8	16
9	Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients. OncoTargets and Therapy, 2017, Volume 10, 3169-3175.	1.0	15
10	The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients. Diagnostics, 2020, 10, 414.	1.3	15
11	Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?. PLoS ONE, 2018, 13, e0194270.	1.1	14
12	The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer. Diagnostics, 2021, 11, 494.	1.3	14
13	Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125. Oncology Letters, 2016, 12, 3101-3114.	0.8	13
14	The Clinical Importance of IL-6, IL-8, and TNF-α in Patients with Ovarian Carcinoma and Benign Cystic Lesions. Diagnostics, 2021, 11, 1625.	1.3	13
15	Endometriosis—A Multifaceted Problem of a Modern Woman. International Journal of Environmental Research and Public Health, 2021, 18, 8177.	1.2	12
16	Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer?. Diagnostics, 2021, 11, 626.	1.3	11
17	Application of Telehealth in Prenatal Care during the COVID-19 Pandemic—A Cross-Sectional Survey of Polish Women. Journal of Clinical Medicine, 2021, 10, 2570.	1.0	11
18	Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers. Journal of Ovarian Research, 2016, 9, 11.	1.3	10

#	Article	IF	Citations
19	Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?. Tumor Biology, 2016, 37, 8879-8887.	0.8	10
20	Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points. Cancers, 2021, 13, 6063.	1.7	8
21	Thrombospondin-I concentrations behavior in plasma of patients with ovarian cancer. Cancer Biomarkers, 2017, 20, 31-39.	0.8	7
22	HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases. Disease Markers, 2017, 2017, 1-13.	0.6	7
23	The role of lipocalin-2 serum levels in the diagnostics of endometrial cancer. Cancer Biomarkers, 2019, 24, 315-324.	0.8	7
24	Complementary Methods in Cancer Treatment—Cure or Curse?. International Journal of Environmental Research and Public Health, 2021, 18, 356.	1.2	6
25	Approaches to the Diagnosis and Management of Ovarian Cancer in Pregnancy. Cancer Management and Research, 2021, Volume 13, 2329-2339.	0.9	6
26	Diagnosis of placental insufficiency independently of clinical presentations using sFlt-1/PLGF ratio, including SGA patients. Pregnancy Hypertension, 2021, 25, 244-248.	0.6	6
27	Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer. Diagnostics, 2022, 12, 251.	1.3	6
28	Herlyn-Werner-Wunderlich Syndrome: Comparison of Two Cases. International Journal of Environmental Research and Public Health, 2020, 17, 7173.	1.2	5
29	Therapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid. International Journal of Environmental Research and Public Health, 2021, 18, 7819.	1.2	5
30	Expression of selected angiogenesis-related small microRNAs in patients with abnormally increased secretion of glucocorticoids. Endokrynologia Polska, 2019, 70, 489-495.	0.3	5
31	MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors. Asian Pacific Journal of Cancer Prevention, 2016, 17, 2597-603.	0.5	5
32	Could Galectin 3 Be a Good Prognostic Factor in Endometrial Cancer?. Diagnostics, 2020, 10, 635.	1.3	4
33	Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer. Diagnostics, 2022, 12, 189.	1.3	4
34	Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin. Journal of Functional Biomaterials, 2019, 10, 55.	1.8	3
35	Metalloproteinases in Endometrial Cancer—Are They Worth Measuring?. International Journal of Molecular Sciences, 2021, 22, 12472.	1.8	3
36	New poly(ester-amide) copolymers modified with polyether (PEAE) for anticancer drug encapsulation. Journal of Microencapsulation, 2016, 33, 702-711.	1.2	2

#	Article	IF	Citations
37	Importance of Potential New Biomarkers in Patient with Serouse Ovarian Cancer. Diagnostics, 2021, 11, 1026.	1.3	2
38	The Analysis of NADPH Quinone Reductase 1 (NQO1) Polymorphism in Polish Patients with Colorectal Cancer. Biomolecules, 2021, 11, 1024.	1.8	2
39	Effectiveness of Different Algorithms and Cut-off Value in Preeclampsia First Trimester Screening. Journal of Pregnancy, 2022, 2022, 1-11.	1.1	2
40	Ectopic pregnancy treatment by combination therapy. Open Medicine (Poland), 2016, 11, 530-536.	0.6	1
41	Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy. Hereditary Cancer in Clinical Practice, 2019, 17, 10.	0.6	1
42	Sexuality of Women after Gynecological Surgeries. Healthcare (Switzerland), 2020, 8, 393.	1.0	1
43	Long-Term Follow-Up of a Female Patient Treated with Olaparib—Hope for a Long Life without Relapse?. International Journal of Environmental Research and Public Health, 2021, 18, 3430.	1.2	1
44	Rhabdomyosarcoma of the Cervix in a Post-Menopausal Woman—An Unparalleled Phenomenon. International Journal of Environmental Research and Public Health, 2021, 18, 7851.	1.2	1
45	Risk model in women with ovarian cancer without mutations. Open Medicine (Poland), 2018, 13, 565-574.	0.6	0
46	Evaluation of indications for amniocentesis in cases of normal fetal ultrasound results. Ginekologia Polska, 2020, 91, 693-699.	0.3	0